Clinical Trial Details
| Trial ID: | L7082 |
| Source ID: | NCT00449605 |
| Associated Drug: | Rimonabant |
| Title: | A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes |
| Acronym: | ALLEGRO |
| Status: | TERMINATED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: Rimonabant|DRUG: Glimepiride|DRUG: Metformin |
| Outcome Measures: | Primary: Change from baseline in glycemic measure HbA1c, 52 weeks (1 year) | Secondary: Absolute change from baseline in body weight, 52 weeks|Relative change from baseline in HDL-C, 52 weeks |
| Sponsor/Collaborators: | Sponsor: Sanofi |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE3 |
| Enrollment: | 508 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT |
| Start Date: | 2007-03 |
| Completion Date: | 2009-03 |
| Results First Posted: | |
| Last Update Posted: | 2016-05-16 |
| Locations: | Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, 08807, United States|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-aventis adminsitrative office, Santiago, Chile|Sanofi-Aventis Administrative Office, Horsholm, Denmark|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Puerto Rico, Puerto Rico|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Bromma, Sweden |
| URL: | https://clinicaltrials.gov/show/NCT00449605 |
